Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, and Tools for Risk of Cardiovascular Disease: A Scientific Statement From the American Heart Association
Recommendations
As issued by the authors
Rigorous evaluation of performance (accuracy, precision, incremental performance when added to contemporary multivariable risk models or established risk factors) and clinical utility (actionability, scalability, generalizability) before adoption in clinical practice
Additional considerations: reproducibility, cost-value (including downstream health care costs) and implications for health equity
Original publication
Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, and Tools for Risk of Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. Published 11 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →